Zoetis (NYSE:ZTS) Price Target Cut to $230.00

Zoetis (NYSE:ZTS) had its target price decreased by Barclays from $260.00 to $230.00 in a research note issued to investors on Tuesday, Benzinga reports. Barclays currently has an overweight rating on the stock.

Several other analysts have also recently commented on the company. Piper Sandler restated an overweight rating and issued a $195.00 target price (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. StockNews.com cut Zoetis from a strong-buy rating to a buy rating in a research report on Tuesday, February 20th. The Goldman Sachs Group lifted their price target on Zoetis from $190.00 to $226.00 and gave the company a buy rating in a research report on Wednesday, January 17th. Finally, Stifel Nicolaus lowered their price target on Zoetis from $215.00 to $195.00 and set a buy rating on the stock in a research report on Tuesday, April 2nd. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of Buy and a consensus price target of $218.00.

Zoetis Stock Up 2.8 %

ZTS opened at $149.56 on Tuesday. Zoetis has a 12 month low of $144.80 and a 12 month high of $201.92. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00. The stock has a market cap of $68.40 billion, a P/E ratio of 29.50, a P/E/G ratio of 2.24 and a beta of 0.85. The stock’s 50 day moving average price is $173.78 and its 200 day moving average price is $179.78.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The business had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.19 billion. During the same quarter in the prior year, the business earned $1.15 earnings per share. The firm’s revenue was up 8.5% compared to the same quarter last year. As a group, research analysts predict that Zoetis will post 5.79 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be paid a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a dividend yield of 1.16%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s dividend payout ratio is presently 34.12%.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of the firm’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $173.33, for a total transaction of $159,983.59. Following the completion of the sale, the executive vice president now directly owns 15,723 shares of the company’s stock, valued at approximately $2,725,267.59. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 2,209 shares of company stock valued at $371,293 in the last three months. 0.15% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Zoetis

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in shares of Zoetis by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 40,334,966 shares of the company’s stock worth $7,960,912,000 after acquiring an additional 536,477 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Zoetis by 31.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock worth $2,707,262,000 after acquiring an additional 3,244,074 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Zoetis by 2.5% in the third quarter. Wellington Management Group LLP now owns 12,344,692 shares of the company’s stock worth $2,147,730,000 after buying an additional 297,044 shares during the period. Capital World Investors boosted its position in shares of Zoetis by 0.6% in the fourth quarter. Capital World Investors now owns 9,064,158 shares of the company’s stock worth $1,788,988,000 after buying an additional 57,798 shares during the period. Finally, Northern Trust Corp boosted its position in shares of Zoetis by 3.3% in the third quarter. Northern Trust Corp now owns 6,143,258 shares of the company’s stock worth $1,068,804,000 after buying an additional 196,771 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.